ALBRIOZA Commercial Launch
CENTAUR Trial Results
Participants Randomized to RELYVRIO Were Observed to Survive Longer Than Those Randomized to Placebo
1
0.8
0.6
Survival
18.7 mo
Probability
0.4
0.2
23.5 mo
wwwwwwwww
AMX0035 + SOC
Placebo + SOC
In a post hoc exploratory, long-
term Intention-to-treat (ITT)
survival analysis using data from
the last participant last visit in
the open-label phase (March
2021), median survival duration
was 23.5 months in the group
originally randomized to
RELYVRIO and 18.7 months in
the group originally randomized
to placebo (4.8-month difference,
HR=0.64, 95% CI=0.416-0.995)*
0
T
0
6
12
18
24
30
36
42
HR (95% CI)
# of events
Cox Regression Model
0.64 (0.416, 0.995)
94
Note: This is an ITT (all 137 patients) analysis
Survival defined as All Cause Mortality (True
Overall Survival)
SOC standard of care; CI = confidence interval; HR = hazard ratio.
*This exploratory analysis should be interpreted cautiously given the limitations of data collected outside of a controlled study, which may be subject to confounding.
AMYLYX | 7View entire presentation